| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...
 
																	JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Neutral and lowers the price target from $121 to $120.
 
																	Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherap...
 
																	
 
																	Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $13...
 
																	https://www.nature.com/articles/d41586-025-03093-6
 
																	JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Neutral and raises the price target from $116 to $121.
 
																	- Reuters